Genelux

    OverviewSuggest Edit

    Genelux is a clinical-stage biopharmaceutical company developing a proprietary oncolytic virus-based technology platform and a pipeline of products with applications for cancer detection and therapy. Its lead oncology product candidate, GL-ONC1, is an attenuated vaccina virus that results in regression and elimination of a range of solid tumors in animals without damaging healthy tissues or organs.
    TypePrivate
    Founded2001
    Websitegenelux.com

    Latest Updates

    Employees (est.) (May 2020)10
    Cybersecurity ratingCMore

    Key People/Management at Genelux

    James L. Tyree

    James L. Tyree

    Chairman
    Thomas Zindrick

    Thomas Zindrick

    President and CEO
    Paul Scigalla

    Paul Scigalla

    Chief Medical Officer
    Tony Yu

    Tony Yu

    Vice President, Clinical Trial Operations
    Joseph Cappello

    Joseph Cappello

    Vice President, Pharmaceutical Development
    John Thomas

    John Thomas

    Director
    Show more

    Genelux Financials and Metrics

    Summary Metrics

    Founding Date

    2001

    Genelux Cybersecurity Score

    Cybersecurity ratingPremium dataset

    C

    79/100

    SecurityScorecard logo

    Genelux Online and Social Media Presence

    Embed Graph

    Genelux Frequently Asked Questions

    • When was Genelux founded?

      Genelux was founded in 2001.

    • Who are Genelux key executives?

      Genelux's key executives are James L. Tyree, Thomas Zindrick and Paul Scigalla.

    • How many employees does Genelux have?

      Genelux has 10 employees.

    • Who are Genelux competitors?

      Competitors of Genelux include ReGen Therapeutics, JCR Pharmaceuticals and GBT (Global Blood Therapeutics).